Market Research Industry Today

Renal Denervation (RDN) Devices Market to Thrive Due to Surge in Hypertension -Transparency Market Research

A new market report published by Transparency Market Research is Renal Denervation Devices Market - Global Industry Analysis, Size, Share, Growth, and Forecast 2012 - 2021
Published 02 November 2015

Renal denervation (RDN) is a minimally invasive procedure used to treat hypertension. Owing to the benefits of RDN devices over drug therapy, the market is projected to grow by leaps and bounds.

Europe Holds Dominant Position in Global RDN Devices Market

Geographically, the global RDN devices market is divided into four main regions: North America, Europe, Asia Pacific, and Rest of the World. With an 80% share in 2012, Europe dominated the worldwide market, followed by Asia Pacific. Europe is also the fastest growing regional renal denervation devices market and is estimated to retain its leading position till 2021. There has been a surge in research and development activities in the field of renal denervation in Europe and numerous devices have gained approval over the past few years. The U.K., France, Italy, and Germany are some of the key RDN devices markets in Europe.

Get Sample Report:

North America, Asia Pacific Emerge as Strong Competitors

FDA approvals for renal denervation devices are projected to rise in the next couple of years, boosting the North America RDN devices market. The increasing incidence of cardiovascular diseases owing to poor lifestyle patterns is another factor that has led to the growing demand for renal denervation devices in the region. Asia Pacific also has a widening patient pool, fuelling the RDN devices market in the region.

Medtronic’s Simplicity Most Widely Used RDN Product

Product-wise, the key renal denervation devices are Boston Scientific’s V2 (Vessix Vascular), Medtronic’s Symplicity, St. Jude’s EnlighHTN, ReCor Medical’s Paradise, and Covidien’s OneShot. Presently, only these five devices have received an approval for CE mark certification. However, no RDN therapy has received approval from the U.S. FDA. In 2012, Medtronic’s Symplicity was the most widely used renal denervation device and held an 85.5% share of the overall market. ReCor Medical’s Paradise is the sole ultrasound denervation system that has a CE certification. Thanks to intense competition among these product manufacturers and the threat of new players, innovative technologies are projected to impact the RDN devices market.

Radiofrequency-based Renal Denervation Devices Hold Largest Share

There are various technologies used in RDN devices such as ultrasound, radiofrequency, micro-infusion, cryoablation, nano-particles, and radiation. Of these, radiofrequency-based renal denervation devices held the largest share of the overall market owing to their benefits of time efficiency, reproducibility, and safety. This segment is projected to continue its dominance over the RDN devices market through 2021. However, the segment is also forecast to face intense competition from other expanding renal denervation technologies.

RDN Devices Market Stimulated by Rising Incidence of Hypertension

The global renal denervation devices market is primarily driven by the growing incidence of uncontrolled hypertension (uHTN) and treatment resistant hypertension (trHTN). An RDN procedure is short and has a permanent effect on the condition of a patient. As a result, the demand for renal denervation devices has gained momentum. Apart from this, the market is also fuelled by the rapid development of renal denervation devices and rise in the global aging population.

Lack of Awareness among Patients Impeding RDN Market

On one hand, there is a shortage of clinical evidence to support the effect of renal denervation devices, which restricts the expansion of the global market. On the other hand, compared to drug-based therapy, there is scant awareness about renal denervation procedures using RDN devices. This, coupled with unstable reimbursement policies, is projected to hamper the growth of the renal denervation devices market.

Renal Denervation Devices Market to Register Outstanding Growth

The global RDN devices market is poised for immense growth till the end of the decade. According to a report by Transparency Market Research, in 2012, the market for renal denervation devices stood at a value of US$88.5 million and is projected to grow to US$1.9 billion by 2021. If this value holds true, the global market will register a CAGR of 41.2% between 2012 and 2021.

Some of the prominent names in the RDN devices market are Boston Scientific Corporation, St. Jude Medical, Kona Medical, Mercator Medsystems, CardioSonic, Medtronic Inc., and Covidien PLC.

Browse Full Global Renal Denervation Devices Market Report With Complete TOC @

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Mr. Nachiket Ghumare
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453


Other Industry News

Ready to start publishing

Sign Up today!